53 Riferimenti bibliografici
Akamine E.H., Hohman T.C., Nigro D., Carvalho M.H., de Cássia Tostes R., Fortes Z.B. Minalrestat, an aldose reductase inhibitor, corrects the impaired microvascular reactivity in diabetes. J Pharmacol Exp Ther. 2003 Mar;304(3):1236-42.
Ansari N.H., Bhatnagar A., Fulep E., Khanna P., Srivastava S.K., Trolox protects hyperglycemia-induced caractogenesis in cultured rat lens. Res. Commun. Chem. Pathol. Pharmacol. 84 (1994) 93-104.
Asano T., Saito Y., Kawakami M., Yamada N., Fidarestat Clinical Pharmacology Study Group. Fidarestat (SNK-860), a potent aldose reductase inhibitor, normalizes the elevated sorbitol accumulation in erythrocytes of diabetic patients. J. Diabetes Complications. 2002 Mar-Apr;16(2):133-8.
Asano T., Saito Y., Kawakami M., Yamada N., Sekino H., Hasegawa S., Fidarestat Clinical Pharmacology Study Group. Erythrocytic sorbitol contents in diabetic patients correlate with blood aldose reductase protein contents and plasma glucose levels, and are normalized by the potent aldose reductase inhibitor fidarestat (SNK-860). J. Diabetes Complications. 2004 Nov-Dec;18(6):336-42.
Beyer-Mears A., Mistry K., Diecke F.P., Cruz E., Zopolrestat prevention of proteinuria, albuminuria and cataractogenesis in diabetes mellitus, Pharmacology. 1996 May;52(5):292-302.
Biadene M., Hazemann I., Cousido A., Ginell S., Joachimiak A., Sheldrick G.M., Podjarny A., Schneider T.R., The atomic resolution structure of human aldose reductase reveals that rearrangement of a bound ligand allows the opening of the safety-belt loop. Acta. Crystallogr. D. Biol. Crystallogr. 2007 Jun;63(Pt 6):665-72. Epub 2007 May 15.
54
Bohren K.M., Brownlee J.M., Milne A.C., Gabbay K.H., Harrison D.H., The structure of Apo R268A human aldose reductase: hinges and latches that control the kinetic mechanism. Biochim. Biophys. Acta. 2005 May 15;1748(2):201-12.
Bohren K.M., Grimshaw C.E., Lai C.J., Harrison D.H., Ringe D., Petsko G.A., Gabbay K.H., Tyrosine-48 is the proton donor and histidine-110 directs substrate stereochemical selectivity in the reduction reaction of human aldose reductase: enzyme kinetics and crystal structure of the Y48H mutant enzyme. Biochemistry. 1994 Mar 1;33(8):2021-32.
Borhani D.W., Harter T.M., Petrash J.M. The crystal structure of the aldose reductase. NADPH binary complex. J. Biol. Chem. 1992 Dec 5;267(34):24841-7.
Boulton A.J., Levin S., Comstock J., A multicentre trial of the aldose-reductase inhibitor, tolrestat, in patients with symptomatic diabetic neuropathy. Diabetologia. 1990 Jul;33(7):431-7.
Brownlee M., Biochemistry and molecular cell biology of diabetic complications, Nature 414 (2001) 813-820.
Cappiello M., Voltarelli M., Giannessi M., Cecconi I., Camici G., Manao G., Del Corso A., Mura U. Glutathione dependent modification of bovine lens aldose reductase., Exp. Eye Res. 1994 Apr;58(4):491-501.
55
Cammarata P.R., Chen H.Q., Yang J., Yorio T., Modulation of myo-[3H]inositol uptake by glucose and sorbitol in culture bovine lens epithelial cells. II. Characterization of high- and low-affinity myo-inositol transport sites, Invest. Ophthalmol. Vis. Sci. 33 (1992) 3572-3580.
Choudhary S., Zhang W., Zhou F., Campbell G.A., Chan L.L., Thompson E.B., Ansari N.H., Cellular lipid peroxidation end-products induce apoptosis in human lens epithelial cells, Free Radic. Biol.Med. 32 (2002) 360-369.
Chung S.S., Ho E.C., Lam K.S., Chung S.K. Contribution of polyol pathway to diabetes-induced oxidative stress, J. Am. Soc. Nephrol. 2003 Aug;14(8 Suppl 3):S233-6.
Del Corso A., Cappiello M., Mura U. From a dull enzyme to something else: facts and perspectives regarding aldose reductase ,Curr. Med. Chem. 2008;15(15):1452-61.
El-Benna J., Dang P.M., Gougerot –Pochidalo M.A., Marie J.C., Braut-Boucher F., p47phox, the phagocyte NADPH oxidase/NOX2 organizer: structure, phosphorylation and implication in disease, Exp. Mol. Med. 41 (2009) 984-995.
Faes T.J., Yff G.A., DeWeerdt O., Lanting P., Heimans J.J., Bertelsmann F.W., Treatment of diabetic autonomic neuropathy with an aldose reductase inhibitor, J. Neurol. 1993;240(3):156-60.
Fagius J., Jameson S., Effects of aldose reductase inhibitor treatment in diabetic polyneuropathy - a clinical and neurophysiological study. J Neurol Neurosurg Psychiatry. 1981 Nov;44(11):991-1001.
Fagius J., Brattberg A., Jameson S., Berne C. Limited benefit of treatment of diabetic polyneuropathy with an aldose reductase inhibitor: a 24-week controlled trial. Diabetologia. 1985 Jun;28(6):323-9.
56
Forman H.J., Torres M., Redox signaling in macrophages, Mol. Aspects Med. 22 (2001) 189-216. Gabbay K.H., Merola L.O., Field R.A. Sorbitol pathway: presence in nerve and cord with substrate accumulation in diabetes., Science 1966 Jan 14;151(3707):209-10.
Gius D., Botero A., Shah S., Curry H.A., Intracellular oxidation/reduction status in the regulation of transcription factors NF-kappaB and AP-1, Toxicol. Lett. 106 (1999), 93-106.
Galkina E., Ley K., Immune and inflammatory mechanism of atherosclerosis, Annu.Rev. Immunol. 27 (2009) 165-197.
Goto Y., Hotta N., Shigeta Y., Sakamoto N., Kikkawa R., Effects of an aldose reductase inhibitor, epalrestat, on diabetic neuropathy. Clinical benefit and indication for the drug assessed from the results of a placebo-controlled double-blind study, Biomed. Pharmacother. 1995;49(6):269-77.
Graham A., Brown L., Hedge P.J., Gammack A.J., Markham A.F. Structure of the human aldose reductase gene, J. Biol. Chem. 1991 Apr 15;266(11):6872-7.
Grimshaw, C.E. (1986) Direct measurement of the rate of ring opening of D-glucose by enzyme catalyzed reduction. Carbohyd. Res. 148, 345-358.
Halliwell B., Mechanism involved in the generation of free radicals, Pathol. Biol. (Paris) 44 (1996) 6-13.
Hamada Y., Araki N., Koh N., Nakamura J., Horiuchi S., Hotta N., Rapid formation of advanced glycation end products by intermediate metabolites of glycolytic pathway and polyol pathway, Biochem. Biophys. Res. Commun. 228 (1996) 539-543.
Harrison D.H., Bohren K.M., Ringe D., Petsko G.A., Gabbay K.H. An anion binding site in human aldose reductase: mechanistic implications for the binding of citrate, cacodylate, and glucose 6-phosphate, Biochemistry. 1994 Mar 1;33(8):2011-20.
57
Hers H.G., Aldose reductase, Biochim. Biophys. Acta. 1960 Jan 1;37:120-6.
Ho E., Chen G., Bray T.M., Supplementation of N-acetylcisteine inhibits NF-kappaB activation and protects against alloxan-induced diabetes in CD-1 mice, FASEB J. 13 (1999) 1845-1854.
Hotta N., Yasuda K., Sumita Y., Sano T., Kakuta H., Nagashima M., Hayashi Y., Yamamoto M., Wakao T., Okuyama M., Kobayashi M., Mori K. Effects of a Novel Aldose Reductase Inhibitor, Fidarestat (SNK-860), on Vibration Perception Threshold and Subjective Symptoms in Patients with Diabetic Polyneuropathy : An Open-Label Pilot Study. Clin. Drug Investig. 2004;24(11):671-80.
Inagaki, K., Miwa, I., and Okuda, J. (1982) Affinity purification and glucose specificity of aldose reductase from bovine lens. Arch. Biochem. Biophys. 216, 337-344.
Jacot J.L., Hosotani H., Glover J.P., Lois N., Robison W.G. Jr. Diabetic-like corneal sensitivity loss in galactose-fed rats ameliorated with aldose reductase inhibitors., J. Ocul. Pharmacol. Ther. 1998 Apr;14(2):169-80.
Jez J.M., Flynn T.G., Penning T.M., A new nomenclature for the aldo-keto reductase superfamily.,Biochem. Pharmacol. 1997 Sep 15;54(6):639-47.
Kang E.S., Kim H.J., Paek K.S., Jang H.S., Chang K.C., Lee J.H., Nishinaka T., Yabe-Nishimura C., Seo H.G., Phorbol ester up-regulates aldose reductase expression in A549 cells: a potential role of aldose reductase in cell cycle modulation, Cell. Mol. Life Sci 62 (2005) 1146-1155.
Karin M., Shaulian E., AP-1: linking hydrogen peroxide and oxidative stress to the control of cell proliferation and death, IUBMB Life 52(2001) 17-24.
Karin M., The regulation of AP-1 activity by mitogen-activated protein kinases, J.Biol.Chem. 270 (1995) 16483-16486.
58
Kato N., Yashima S., Suzuki T., Nakayama Y., Jomori T. Long-term treatment with fidarestat suppresses the development of diabetic retinopathy in STZ-induced diabetic rats. J Diabetes Complications. 2003 Nov-Dec;17(6):374-9.
Kern T.S., Engerman R.L. Aldose reductase and the development of renal disease in diabetic dogs. J. Diabetes Complications. 1999 Jan-Feb;13(1):10-6.
King G.L., Shiba T., Oliver J., Inoguchi T., Bursell S.E., Cellular and molecular abnormalities in the vascular endothelium of diabetes mellitus, Annu. Rev. Med. 45 (1994) 179-188.
Klebe G., Krämer O., Sotriffer C. Strategies for the design of inhibitors of aldose reductase, an enzyme showing pronounced induced-fit adaptations, Cell. Mol. Life Sci. 2004 Apr;61(7-8):783-93.
Lee A.Y., Chung S.K., Chung S.S., Demonstration that polyol accumulation is responsible for diabetic cataract by the use of transgenic mice expressing the aldose reductase gene in the lens, Proc. Natl. Acad. Sci. U. S. A. 92 (1995) 2780-2784.
Lee J.Y., Je J.H., Kim D.H., Chung S.W., Zou Y., Kim N.D., Ae Yoo M., Suck Baik H., Yu B.P., Chung H.Y., Induction of endothelial apoptosis by 4-hydroxyexenal, Eur. J. Biochem. 271 (2004) 1339-1347.
Musashi M., Ota S., Shiroshita N., The role of protein Kinase C isoforms in cell proliferation and apoptosis, Int J. Hematol. 72 (2002) 12-19.
Mylari B.L., Larson E.R., Beyer T.A., Zembrowski W.J., Aldinger C.E., Dee M.F., Siegel T.W., Singleton D.H., Novel, potent aldose reductase inhibitors: 3,4-dihydro-4-oxo-3-[[5-(trifluoromethyl)-2-benzothiazolyl] methyl]-1-phthalazineacetic acid (zopolrestat) and congeners., J Med. Chem. 1991 Jan;34(1):108-22.
59
Nadkarni D.V., Sayre L.M., Structural definition of early lysine and histidine adduction chemistry of 4-hydroxynonenal, Chem. Res. Toxicol. 8 (1995) 284-291.
Nagaraj R.H., Prabhakaram M., Ortwerth B.J., Monnier V.M., Suppression of pentosidine formation in galactosemic rat lens by an inhibitor of aldose reductase, Diabetes 43 (1994) 580-586.
Obrador E., Navarro J., Mompo J., Asensi M., Pellicer J.A., Estrela J.M., Regulation of tumor cell sensivity to TNFα-induced oxidative stress and citotoxicity: role of glutathione, Biofactors 8 (1998) 23-26.
O'Hare J.P., Morgan M.H., Alden P., Chissel S., O'Brien I.A., Corrall R.J. Aldose reductase inhibition in diabetic neuropathy: clinical and neurophysiological studies of one year's treatment with sorbinil. Diabet Med. 1988 Sep;5(6):537-42.
Podjarny A., Cachau R.E., Schneider T., Van Zandt M., Joachimiak A. Subatomic and atomic crystallographic studies of aldose reductase: implications for inhibitor binding, Cell. Mol. Life Sci. 2004 Apr;61(7-8):763-73.
Ramana K.V., Friedrich B., Tammali R., West M.B, Bhatnagar A., Srivastava S.K., Requirement of aldose reductase for the hyperglycemic activation of protein kinase C and formation of diacylglycerol in vascular smooth muscle cells, Diabetes 54 (2005) 818-829.
Robison W.G. Jr., Jacot J.L., Glover J.P., Basso M.D., Hohman T.C. Diabetic-like retinopathy: early and late intervention therapies in galactose-fed rats., Invest. Ophthalmol. Vis. Sci. 1998 Sep;39(10):1933-41.
Rondeau J.M., Tête-Favier F., Podjarny A., Reymann J.M., Barth P., Biellmann J.F., Moras D. Novel NADPH-binding domain revealed by the crystal structure of aldose reductase, Nature. 1992 Jan 30;355(6359):469-72.
60
Passariello N., Sepe J., Marrazzo G., De Cicco A., Peluso A., Pisano M.C., Sgambato S., Tesauro P., D'Onofrio F., Effect of aldose reductase inhibitor (tolrestat) on urinary albumin excretion rate and glomerular filtration rate in IDDM subjects with nephropathy. Diabetes Care. 1993 May;16(5):789-95.
Samuels L.T., Harding B.W., Mann T. Aldose reductase and ketose reductase in male accessory organs of reproduction. Distribution and relation to seminal fructose., Biochem J. 1962 Jul 84:39-45.
Santiago J.V., Snksen P.H., Boulton A.J., Macleod A., Beg M., Bochenek W., Graepel G.J., Gonen B., Withdrawal of the aldose reductase inhibitor tolrestat in patients with diabetic neuropathy: effect on nerve function. The Tolrestat Study Group. J Diabetes Complications. 1993 Jul-Sep;7(3):170-8.
Spielberg S.P., Shear N.H., Cannon M., Hutson N.J., Gunderson K. In-vitro assessment of a hypersensitivity syndrome associated with sorbinil. Ann Intern Med. 1991 May 1;114(9):720-4.
Spycher S., Tabataba-Vakili S., O’Donnell V.B., Palomba L., Azzi A., 4-hydroxi-2,3-trans-nonenal induces transcriptional and expression of aldose reductase, Biochem. Biophys. Res. Commun. 226 (1996) 512-516.
Tammali R., Ramana K.V., Srivastava S.K., Aldose reductase regulates TNF-alpha-induced PGE2 production in human colon cancer cells, Cancer Lett. 252 (2007) 299-306.
Tang W.H., Martin K.A., Hwa J. Aldose reductase, oxidative stress, and diabetic mellitus, Front. Pharmacol. 2012 May 9;3:87. doi: 10.3389/fphar.2012.00087. eCollection 2012.
Uemura M., Manabe H., Yoshida N., Fujita N., Ochiai J., Matsumoto N., Takagi T., Naito Y., Yoshikawa T., Alpha- tocopherol prevents apoptosis of vascular endothelial cells via a mechanism exceeding that of mere antoixidation, Eur. J. Pharmacol. 456 (2002) 29-37.
61
Uchida K., Kigoshi T., Nakano S., Ishii T., Kitazawa M., Morimoto S., Effect of 24 weeks of treatment with epalrestat, an aldose reductase inhibitor, on peripheral neuropathy in patients with non-insulin-dependent diabetes mellitus. Clin. Ther. 1995 May-Jun;17(3):460-6.
Urzhumtsev A., Tête-Favier F., Mitschler A., Barbanton J., Barth P., Urzhumtseva L., Biellmann J.F., Podjarny A., Moras D., A 'specificity' pocket inferred from the crystal structures of the complexes of aldose reductase with the pharmaceutically important inhibitors tolrestat and sorbinil. Structure. 1997 May 15;5(5):601-12.
Van Heyningen R. Metabolism of xylose by the lens, 2. Rat lens in vivo and in vitro. Biochem. J. 1959 Sep;73:197-207
Vander Jagt D.L., Kolb N.S., Vander Jagt T.J., Chino J., Martinez F.J., Hunsaker L.A., Royer R.E. Substrate specificity of human aldose reductase: identification of 4-hydroxynonenal as an endogenous substrate, Biochim. Biophys. Acta. 1995 Jun 12;1249(2):117-26.
Wilson D.K., Bohren K.M., Gabbay K.H., Quiocho F.A. An unlikely sugar substrate site in the 1,65 A structure of the human aldose reductase holoenzyme implicated in diabetic complications, Science 1992 Jul 3;257(5066):81-4.
Wilson D.K., Tarle I., Petrash J.M., Quiocho F.A. Refined 1,8 A structure of human aldose reductase complexed with the potent inhibitor zopolrestat, Proc. Natl. Acad. Sci. U. S. A. 1993 Nov 1;90(21):9847-51.
Ziegler D., Mayer P., Rathmann W., Gries F.A., One-year treatment with the aldose reductase inhibitor, ponalrestat, in diabetic neuropathy. Diabetes Res. Clin. Pract. 1991 Oct;14(1):63-73.
